Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Respiratory Syncytial Virus (RSV) Infections-Pipeline Review, H1 2015

Respiratory Syncytial Virus (RSV) Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Respiratory Syncytial Virus (RSV) Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections-Pipeline Review, H1 2015', provides an overview of the Respiratory Syncytial Virus (RSV) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Respiratory Syncytial Virus (RSV) Infections Overview 11

Therapeutics Development 12

Pipeline Products for Respiratory Syncytial Virus (RSV) Infections-Overview 12

Pipeline Products for Respiratory Syncytial Virus (RSV) Infections-Comparative Analysis 13

Respiratory Syncytial Virus (RSV) Infections-Therapeutics under Development by Companies 14

Respiratory Syncytial Virus (RSV) Infections-Therapeutics under Investigation by Universities/Institutes 19

Respiratory Syncytial Virus (RSV) Infections-Pipeline Products Glance 21

Clinical Stage Products 21

Early Stage Products 22

Respiratory Syncytial Virus (RSV) Infections-Products under Development by Companies 23

Respiratory Syncytial Virus (RSV) Infections-Products under Investigation by Universities/Institutes 28

Respiratory Syncytial Virus (RSV) Infections-Companies Involved in Therapeutics Development 29

3-V Biosciences, Inc. 29

Ablynx NV 30

ADMA Biologics, Inc. 31

Agilvax, Inc. 32

AlphaVax, Inc. 33

AmVac AG 34

Aridis Pharmaceuticals LLC 35

Artificial Cell Technologies, Inc. 36

Astellas Pharma Inc. 37

AstraZeneca Plc 38

Bavarian Nordic A/S 39

Biota Pharmaceuticals, Inc. 40

Celltrion, Inc. 41

Codagenix, Inc. 42

Crucell N.V. 43

CureVac GmbH 44

Emergent BioSolutions Inc. 45

Evec, Inc. 46

F. Hoffmann-La Roche Ltd. 47

GenVec, Inc. 48

Gilead Sciences, Inc. 49

GlaxoSmithKline Plc 50

Humabs BioMed SA 51

iBio, Inc. 52

Immunovaccine, Inc. 53

Johnson & Johnson 54

Kineta, Inc. 55

MedImmune, LLC 56

Medivir AB 57

Merck & Co., Inc. 58

Microbiotix, Inc. 59

MSM Protein Technologies, Inc. 60

Mucosis B.V. 61

NanoBio Corporation 62

Navigen Pharmaceuticals, Inc. 63

Novavax, Inc. 64

Panacea Biotec Limited 65

Pulmocide Ltd 66

Regeneron Pharmaceuticals, Inc. 67

REPLICor Inc. 68

Romark Laboratories, L.C. 69

Sirnaomics, Inc. 70

Spring Bank Pharmaceuticals, Inc. 71

Symphogen A/S 72

Takeda Pharmaceutical Company Limited 73

TechnoVax, Inc. 74

Vaxart, Inc. 75

Virometix AG 76

Respiratory Syncytial Virus (RSV) Infections-Therapeutics Assessment 77

Assessment by Monotherapy Products 77

Assessment by Combination Products 78

Assessment by Target 79

Assessment by Mechanism of Action 81

Assessment by Route of Administration 83

Assessment by Molecule Type 85

Drug Profiles 87

AK-0529-Drug Profile 87

ALS-8112-Drug Profile 88

ALS-8176-Drug Profile 89

ALX-0171-Drug Profile 90

AMV-601-Drug Profile 92

AMV-602-Drug Profile 93

AMV-603-Drug Profile 94

AMV-611-Drug Profile 95

AR-201-Drug Profile 96

AZ-27-Drug Profile 97

BTAC-585-Drug Profile 98

danirixin-Drug Profile 99

DPX-RSV-Drug Profile 101

Drugs to Inhibit STAT for RSV Infection-Drug Profile 102

EV-046120-Drug Profile 103

EV-046135-Drug Profile 104

GBV-006-Drug Profile 105

GSK-3003891A-Drug Profile 106

GV-2311-Drug Profile 107

human parainfluenza virus [type 1] + respiratory syncytial virus vaccine-Drug Profile 108

IKT-041-Drug Profile 109

influenza + RSV vaccine-Drug Profile 110

JNJ-53718678-Drug Profile 111

JNJ-61187191-AAA-Drug Profile 112

MBX-300-Drug Profile 113

MEDI-7510-Drug Profile 115

MEDI-8897-Drug Profile 117

Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections-Drug Profile 118

Monoclonal Antibody for Respiratory Syncytial Virus-Drug Profile 119

Monoclonal Antibody for RSV Infections-Drug Profile 120

Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections-Drug Profile 121

MPE-8-Drug Profile 122

MSM-605-Drug Profile 123

MVA-BN-RSV-Drug Profile 124

MVA-RSV-Drug Profile 125

Oligonucleotide for Respiratory Syncytial Viral Infections-Drug Profile 126

palivizumab biosimilar-Drug Profile 127

palivizumab biosimilar-Drug Profile 128

palivizumab biosimilar-Drug Profile 129

pertussis [strain BPZE1] vaccine-Drug Profile 130

presatovir-Drug Profile 131

Recombinant Protein for RSV Infections-Drug Profile 132

REGN-2222-Drug Profile 133

REP-9-Drug Profile 134

respiratory syncytial virus like particle vaccine-Drug Profile 135

respiratory syncytial virus like particle vaccine-Drug Profile 136

respiratory syncytial virus vaccine-Drug Profile 137

respiratory syncytial virus vaccine-Drug Profile 139

respiratory syncytial virus vaccine-Drug Profile 140

respiratory syncytial virus vaccine-Drug Profile 143

respiratory syncytial virus vaccine-Drug Profile 144

respiratory syncytial virus vaccine-Drug Profile 145

respiratory syncytial virus vaccine-Drug Profile 147

respiratory syncytial virus vaccine-Drug Profile 148

respiratory syncytial virus vaccine-Drug Profile 149

respiratory syncytial virus vaccine-Drug Profile 150

respiratory syncytial virus vaccine-Drug Profile 151

respiratory syncytial virus vaccine-Drug Profile 153

respiratory syncytial virus vaccine-Drug Profile 154

respiratory syncytial virus vaccine-Drug Profile 155

respiratory syncytial virus vaccine-Drug Profile 156

respiratory syncytial virus vaccine-Drug Profile 157

respiratory syncytial virus vaccine-Drug Profile 158

respiratory syncytial virus vaccine 1-Drug Profile 159

respiratory syncytial virus vaccine 2-Drug Profile 160

respiratory syncytical virus + influenza vaccine-Drug Profile 161

RI-002-Drug Profile 162

RNAi Oligonucleotide for Respiratory Syncytial Virus Infection-Drug Profile 164

RNAi Oligonucleotides for RSV and Viral Respiratory Tract Infections-Drug Profile 165

rOAS-Drug Profile 166

RSV [strain 98-25147-X] vaccine-Drug Profile 167

RSV vaccine-Drug Profile 168

RSV vaccine-Drug Profile 169

RSV vaccine-Drug Profile 170

RSV virus like particle vaccine-Drug Profile 171

RSV-001-Drug Profile 172

RV-521-Drug Profile 173

SB-9200-Drug Profile 174

Small Molecule to Agonize IRF-3 for Viral Infections-Drug Profile 176

Small Molecules for Respiratory Syncitial Virus and Herpes Simplex Virus Infections-Drug Profile 177

Small Molecules for Respiratory Syncytial Virus Infections-Drug Profile 178

Small Molecules for RSV and Influenza A Infections-Drug Profile 179

Small Molecules for RSV Infections-Drug Profile 180

Small Molecules to Inhibit Fatty Acid Synthase for Viral Infections-Drug Profile 181

Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections-Drug Profile 182

Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections-Drug Profile 183

STP-902-Drug Profile 184

Sym-003-Drug Profile 185

Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection-Drug Profile 186

TVX-004IP-Drug Profile 187

Respiratory Syncytial Virus (RSV) Infections-Recent Pipeline Updates 188

Respiratory Syncytial Virus (RSV) Infections-Dormant Projects 208

Respiratory Syncytial Virus (RSV) Infections-Discontinued Products 211

Respiratory Syncytial Virus (RSV) Infections-Product Development Milestones 212

Featured News & Press Releases 212

Appendix 220

Methodology 220

Coverage 220

Secondary Research 220

Primary Research 220

Expert Panel Validation 220

Contact Us 220

Disclaimer 221

List of Tables

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2015 18

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 21

Number of Products under Development by Companies, H1 2015 (Contd..1) 22

Number of Products under Development by Companies, H1 2015 (Contd..2) 23

Number of Products under Development by Companies, H1 2015 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Development, H1 2015 28

Products under Development by Companies, H1 2015 29

Products under Development by Companies, H1 2015 (Contd..1) 30

Products under Development by Companies, H1 2015 (Contd..2) 31

Products under Development by Companies, H1 2015 (Contd..3) 32

Products under Development by Companies, H1 2015 (Contd..4) 33

Products under Investigation by Universities/Institutes, H1 2015 34

Respiratory Syncytial Virus (RSV) Infections-Pipeline by 3-V Biosciences, Inc., H1 2015 35

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Ablynx NV, H1 2015 36

Respiratory Syncytial Virus (RSV) Infections-Pipeline by ADMA Biologics, Inc., H1 2015 37

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Agilvax, Inc., H1 2015 38

Respiratory Syncytial Virus (RSV) Infections-Pipeline by AlphaVax, Inc., H1 2015 39

Respiratory Syncytial Virus (RSV) Infections-Pipeline by AmVac AG, H1 2015 40

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Aridis Pharmaceuticals LLC, H1 2015 41

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Artificial Cell Technologies, Inc., H1 2015 42

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Astellas Pharma Inc., H1 2015 43

Respiratory Syncytial Virus (RSV) Infections-Pipeline by AstraZeneca Plc, H1 2015 44

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Bavarian Nordic A/S, H1 2015 45

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Biota Pharmaceuticals, Inc., H1 2015 46

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Celltrion, Inc., H1 2015 47

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Codagenix, Inc., H1 2015 48

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Crucell N.V., H1 2015 49

Respiratory Syncytial Virus (RSV) Infections-Pipeline by CureVac GmbH, H1 2015 50

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Emergent BioSolutions Inc., H1 2015 51

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Evec, Inc., H1 2015 52

Respiratory Syncytial Virus (RSV) Infections-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 53

Respiratory Syncytial Virus (RSV) Infections-Pipeline by GenVec, Inc., H1 2015 54

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Gilead Sciences, Inc., H1 2015 55

Respiratory Syncytial Virus (RSV) Infections-Pipeline by GlaxoSmithKline Plc, H1 2015 56

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Humabs BioMed SA, H1 2015 57

Respiratory Syncytial Virus (RSV) Infections-Pipeline by iBio, Inc., H1 2015 58

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Immunovaccine, Inc., H1 2015 59

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Johnson & Johnson, H1 2015 60

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Kineta, Inc., H1 2015 61

Respiratory Syncytial Virus (RSV) Infections-Pipeline by MedImmune, LLC, H1 2015 62

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Medivir AB, H1 2015 63

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Merck & Co., Inc., H1 2015 64

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Microbiotix, Inc., H1 2015 65

Respiratory Syncytial Virus (RSV) Infections-Pipeline by MSM Protein Technologies, Inc., H1 2015 66

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Mucosis B.V., H1 2015 67

Respiratory Syncytial Virus (RSV) Infections-Pipeline by NanoBio Corporation, H1 2015 68

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 69

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Novavax, Inc., H1 2015 70

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Panacea Biotec Limited, H1 2015 71

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Pulmocide Ltd, H1 2015 72

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 73

Respiratory Syncytial Virus (RSV) Infections-Pipeline by REPLICor Inc., H1 2015 74

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Romark Laboratories, L.C., H1 2015 75

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Sirnaomics, Inc., H1 2015 76

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2015 77

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Symphogen A/S, H1 2015 78

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 79

Respiratory Syncytial Virus (RSV) Infections-Pipeline by TechnoVax, Inc., H1 2015 80

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Vaxart, Inc., H1 2015 81

Respiratory Syncytial Virus (RSV) Infections-Pipeline by Virometix AG, H1 2015 82

Assessment by Monotherapy Products, H1 2015 83

Assessment by Combination Products, H1 2015 84

Number of Products by Stage and Target, H1 2015 86

Number of Products by Stage and Mechanism of Action, H1 2015 88

Number of Products by Stage and Route of Administration, H1 2015 90

Number of Products by Stage and Molecule Type, H1 2015 92

Respiratory Syncytial Virus (RSV) Infections Therapeutics-Recent Pipeline Updates, H1 2015 194

Respiratory Syncytial Virus (RSV) Infections-Dormant Projects, H1 2015 214

Respiratory Syncytial Virus (RSV) Infections-Dormant Projects (Contd..1), H1 2015 215

Respiratory Syncytial Virus (RSV) Infections-Dormant Projects (Contd..2), H1 2015 216

Respiratory Syncytial Virus (RSV) Infections-Discontinued Products, H1 2015 217

List of Figures

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2015 18

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 20

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Products, H1 2015 28

Assessment by Monotherapy Products, H1 2015 83

Number of Products by Top 10 Targets, H1 2015 85

Number of Products by Stage and Top 10 Targets, H1 2015 85

Number of Products by Top 10 Mechanism of Actions, H1 2015 87

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 87

Number of Products by Top 10 Routes of Administration, H1 2015 89

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 89

Number of Products by Top 10 Molecule Types, H1 2015 91

Number of Products by Stage and Top 10 Molecule Types, H1 2015 91

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3-V Biosciences, Inc.

Ablynx NV

ADMA Biologics, Inc.

Agilvax, Inc.

AlphaVax, Inc.

AmVac AG

Aridis Pharmaceuticals LLC

Artificial Cell Technologies, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Bavarian Nordic A/S

Biota Pharmaceuticals, Inc.

Celltrion, Inc.

Codagenix, Inc.

Crucell N.V.

CureVac GmbH

Emergent BioSolutions Inc.

Evec, Inc.

F. Hoffmann-La Roche Ltd.

GenVec, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Humabs BioMed SA

iBio, Inc.

Immunovaccine, Inc.

Johnson & Johnson

Kineta, Inc.

MedImmune, LLC

Medivir AB

Merck & Co., Inc.

Microbiotix, Inc.

MSM Protein Technologies, Inc.

Mucosis B.V.

NanoBio Corporation

Navigen Pharmaceuticals, Inc.

Novavax, Inc.

Panacea Biotec Limited

Pulmocide Ltd

Regeneron Pharmaceuticals, Inc.

REPLICor Inc.

Romark Laboratories, L.C.

Sirnaomics, Inc.

Spring Bank Pharmaceuticals, Inc.

Symphogen A/S

Takeda Pharmaceutical Company Limited

TechnoVax, Inc.

Vaxart, Inc.

Virometix AG

Respiratory Syncytial Virus (RSV) Infections Therapeutic Products under Development, Key Players in Respiratory Syncytial Virus (RSV) Infections Therapeutics, Respiratory Syncytial Virus (RSV) Infections Pipeline Overview, Respiratory Syncytial Virus (RSV) Infections Pipeline, Respiratory Syncytial Virus (RSV) Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com